Bassil Dahiyat, Xencor CEO
June 13, 2024 10:58 AM EDT
Deals
R&D

J&J re­turns bis­pe­cif­ic T cell en­gager to Xen­cor, re­duc­ing scope of part­ner­ship

Ayisha Sharma

News Reporter

John­son & John­son is hand­ing back a bis­pe­cif­ic T cell en­gager pro­gram to its part­ner Xen­cor, end­ing a sig­nif­i­cant piece of an agree­ment be­tween the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times